DehydraTECH-sildenafil
Erectile Dysfunction
Key Facts
About Lexaria Bioscience
Lexaria Bioscience is a micro-cap biotech focused on commercializing its proprietary DehydraTECH™ drug delivery platform. The company's mission is to improve the performance of existing and new oral pharmaceuticals, particularly fat-soluble molecules, by increasing their bioavailability and onset speed. Its strategy is purely licensing-based, partnering with established pharmaceutical and consumer product companies to integrate DehydraTECH into their pipelines. Key achievements include a robust global patent portfolio, positive human clinical data across multiple drug classes, and a lean operational structure that extends its capital runway.
View full company profileTherapeutic Areas
Other Erectile Dysfunction Drugs
| Drug | Company | Phase |
|---|---|---|
| CF602 | Can Fite Biopharma | Preclinical |
| Sildenafil Formulation | InnovaZone Labs | Approved |
| Rigi10™ Malleable Penile Prosthesis | Rigicon | Approved |
| UNITED Study (Investigational Inflatable Penile Prosthesis) | Rigicon | Clinical Investigation |
| ASP-001 | Aspargo Laboratories | Approved |
| Sildenafil-loaded Z-pods® | Atticus Pharma | Pre-clinical |
| FGF-based Therapeutic | Venturis Therapeutics | Pre-clinical |